Skip to Main Content

Paper Details

Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary.
Urology
9
2021
Androgen, Hormone-Sensitive Prostate Cancer, Prostate Cancer, abiraterone, androgen, apalutamide, docetaxel, enzalutamide, hormone-sensitive prostate cancer, mHSPC, metastatic hormone-sensitive prostate cancer, patient, prednisone
Author NameAffiliation
Maha HussainRobert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine
Himisha BeltranLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Himisha BeltranLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Alexander W WyattUniversity of British Columbia
Howard I ScherMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College
Felix Y Fengand Medicine University of California san francisco
Gerhardt AttardUniversity College London Cancer Institute
Eric A KleinGenitourinary Malignancies Research Center, Cleveland Clinic, Glickman Urological and Kidney Institute
  • 1 - 8

Datasets

Release 1.2